![](https://static.biospace.com/dims4/default/d97b7c4/2147483647/strip/true/crop/1146x239+0+181/resize/1440x300!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2F58%2F72%2F949de5b94cd48aa1ac08e29ba5e6%2Fcompany-profile-default-header-1.png)
![SonoThera.png](https://static.biospace.com/dims4/default/c1d1008/2147483647/strip/true/crop/360x180+0+0/resize/200x100!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2F90%2F80%2F327090b648278e86f9f86c260323%2Fsonothera.png)
SonoThera
Our mission is to develop genetic medicines that treat the root cause of human disease.
SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. We aim to improve the lives and health of millions of people.
NEWS
Looking for a biopharma job? Check out the BioSpace list of 11 top companies hiring life sciences professionals like you.
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
SonoThera closed its Series A round of financing Monday, counting $60.75 million in earnings and will use these proceeds to advance its ultrasound-guided, non-viral gene therapy platform.
JOBS
IN THE PRESS